Haemophilia A
Haemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII, leading to prolonged bleeding after injuries or surgery and spontaneous bleeding episodes.
Severe Hemophilia A: Efanesoctocog Alfa Study
We are comparing a new treatment, efanesoctocog alfa, with other existing therapies for severe hemophilia A. This study aims to understand how well it works in managing the condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitaetsklinikum Bonn AöR
Experimental Haematology and Transfusion Medicine
Bonn, Germany
Universitaetsklinikum Frankfurt AöR
Hematology
Frankfurt am Main, Germany
Azienda Ospedaliero Universitaria Careggi
Center for Bleeding Clinical Trial Unit-1 (CTU-1)
Florence, Italy
Sponsor: Swedish Orphan Biovitrum AB (publ)
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.